Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2022-05-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙独立董事候选人声明（齐珺）
Regulatory Filings Classification · 95% confidence The document is a declaration by an independent director candidate affirming qualifications, independence, and compliance with regulatory requirements for serving as an independent director. It does not contain financial data, audit results, or company performance information. It is not a report or announcement of financial results, nor a regulatory filing about shareholding or management changes. The content is a formal statement related to governance and compliance with listing rules, but it is not a governance report or proxy solicitation. Given the nature of the document as a formal declaration related to director qualifications and independence, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other categories.
2022-05-24 Chinese
马应龙关于召开2021年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of the company 马应龙药业集团股份有限公司. It includes information about the date, voting methods, agenda items to be discussed and voted on, instructions for shareholders, and proxy forms. The document does not contain financial statements or results but rather the meeting logistics and agenda. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document length is over 5,000 characters and is not merely an announcement of a report publication, so it is not RPA. It is not a voting results declaration (DVA) because it does not provide voting outcomes, only the meeting notice and agenda. Therefore, the correct classification is AGM-R with high confidence.
2022-05-24 Chinese
马应龙关于使用闲置自有资金委托理财额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company 马应龙药业集团股份有限公司 regarding the use of idle self-owned funds for entrusted financial management. It details the purpose, amount, types of financial products, risk analysis, risk control measures, and the decision-making process related to the entrusted financial management. It also includes data on the company's recent use of such funds. The document is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is a regulatory announcement about the company's financing activities, specifically the use of idle funds for low-risk financial products. The document length is 2699 characters, which is relatively short and focused on a specific financing update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-05-24 Chinese
马应龙关于修订《公司章程》的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors of 马应龙药业集团股份有限公司 regarding the revision of the company's Articles of Association (公司章程). It details changes to the company's business scope and states that the changes will be submitted to the shareholders' meeting for approval. The document is short (910 characters) and is a formal announcement of a governance change rather than the full governance report or the amended Articles themselves. It does not contain financial data or detailed governance rules but announces a governance-related update. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in company governance or board decisions.
2022-05-24 Chinese
马应龙独立董事关于第十届董事会第十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific board meeting matters, including the use of idle funds for entrusted financial management and the election of board members. It references compliance with company rules and laws, and it is focused on board-level decisions and governance matters. There is no financial data or report content, nor is it an announcement of a report publication. The content aligns with Board/Management Information, specifically announcements or opinions related to board meetings and management decisions.
2022-05-24 Chinese
马应龙2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2022. The report explicitly states it is unaudited and covers the period January to March 2022. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.